SARASOTA, Fla., Sept. 13, 2005 (PRIMEZONE) -- DNAPrint genomics, Inc. (OTCBB:DNAG) today announced that its DNAWitness(tm) forensics technology for law enforcement will be featured in an episode this week on Court TV(r)'s "Forensics Files(r)" program.
When authorities in Louisiana hit a stone wall in their search for a serial killer, they turned to DNAPrint genomics and its DNAWitness(tm) forensics technology for help in analyzing the DNA of the killer lifted from the crime scene. In a surprising twist, viewers will see how DNAPrint's analysis of the DNA changed the course of the investigation and led to the capture of the killer.
The program, entitled "Tight-Fitting Genes," is scheduled for broadcast on Wednesday, Sept. 14, at 9 p.m. Eastern time. Viewers are advised to keep in mind that program schedules are subject to change.
About DNAPrint genomics, Inc.
DNAPrint genomics, Inc. (www.dnaprint.com) is a developer of genomics-based products and services focused on drug development, pharmacogenomic diagnostic tests, forensics technology and consumer genetic tests. The Company's first theranostic product (drug/test combination) is PT-401, a "Super EPO" (erythropoietin) dimer protein drug for treatment of anemia in renal dialysis patients (end stage renal disease). Currently in pre-clinical development, PT-401 will be targeted to patients with a genetic profile indicating their propensity to have the best clinical response. DNAPrint's family of products for the law enforcement forensics and consumer markets include DNAWitness(tm) RETINOME(tm), ANCESTRYbyDNA(tm), and EURO-DNA(tm).
Forward-Looking Statements
All statements in this press release that are not historical are forward-looking statements. Such statements are subject to risks and uncertainties that could cause actual results to differ materially from those projected, including, but not limited to, uncertainties relating to technologies, product development, manufacturing, market acceptance, cost and pricing of DNAPrint's products, dependence on collaborations and partners, regulatory approvals, competition, intellectual property of others, and patent protection and litigation. DNAPrint genomics, Inc. expressly disclaims any obligation or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in DNAPrint's expectations with regard thereto or any change in events, conditions, or circumstances on which any such statements are based.